Search

Displaying results 2501 - 2510 of 7600 in total
  1. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    It was rejected for approval for use in the United States. … It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite.

  2. Drug

    Nemolizumab

    go.drugbank.com/drugs/DB15252
    ApprovedInvestigational

    [A264274] It was later approved by the FDA on August 13, 2024, for the treatment of prurigo nodularis.[L51169] … [L51159] Nemolizumab gained its first global approval in Japan on March 28, 2022, for the treatment of atopic dermatitis.

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  3. Drug

    Dirithromycin

    go.drugbank.com/drugs/DB00954
    Investigational

    Dirithromycin is a macrolide glycopeptide antibiotic used to treat many different types of bacterial infections, such as bronchitis, pneumonia, tonsillitis, and even skin infections.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Nalidixic acid

    go.drugbank.com/drugs/DB00779
    ApprovedWithdrawn

    Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.

    Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  5. Drug

    Olezarsen

    go.drugbank.com/drugs/DB18728
    ApprovedInvestigational

    [L52033] On December 19, 2024, olezarsen was approved by the FDA for the treatment of familial chylomicronemia syndrome.[L52028] It is also being investigated for the treatment of hyperlipidemia. … Olezarsen is an antisense oligonucleotide that targets the messenger RNA (mRNA) for apolipoprotein C-III (APOC3, apoC-III),[L52033] which is a key regulator of triglyceride levels in plasma, in the liver

    Categories: Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia
  6. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    Cariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]

  7. Drug

    Enasidenib

    go.drugbank.com/drugs/DB13874
    ApprovedInvestigational

    Patients eligible for this treatment are selected by testing the presence of IDH2 mutations in the blood or bone marrow. … Enasidenib is an orally available treatment for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2)

  8. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    Acetohexamide has been discontinued in the US market.

  9. Drug

    Cannabidiol

    go.drugbank.com/drugs/DB09061
    ApprovedInvestigational

    It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. … It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS).

  10. Drug

    Rindopepimut

    go.drugbank.com/drugs/DB05374
    Investigational

    The US FDA granted it Breakthrough Therapy Designation for glioblastoma in Feb 2015.